文献速递湿疹皮炎与荨麻疹

克立硼罗软膏治疗儿童及成人特应性皮炎的获益幅度:一项批判性评价

Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal.
PubMed 文献 · Br J Dermatol · 2017-12-03

本文基于两项 III 期随机双盲对照试验(AD-301 和 AD-302),评估克立硼罗软膏治疗轻中度特应性皮炎(AD)的疗效与安全性。作者认为克立硼罗安全且可改善疾病严重度、瘙痒和体征,但获益幅度并不令人乐观。

要点

  • 克立硼罗在 AD-302 中达到主要终点的比例显著优于基质,但 AD-301 未达统计学显著。
  • 克立硼罗可改善瘙痒和 AD 体征,且未发现与治疗相关的严重不良事件。
  • 两项试验主要终点结果不一致,需谨慎解读其临床获益幅度。

核心结论

  • 克立硼罗是安全的,可改善 AD 的疾病严重度、瘙痒和临床体征。
  • 但作者认为其获益幅度并不令人乐观。

研究设计与样本

  • 两项设计相同的多中心、双盲、随机对照 III 期试验(AD-301 和 AD-302),在美国开展。
  • AD-301 和 AD-302 分别有 47 和 42 个研究中心。
  • 参与者按 2:1 随机接受克立硼罗或基质治疗。
  • 纳入年龄≥2 岁、临床诊断 AD(Hanifin 和 Rajka 标准)、皮损面积≥5% 体表面积、基线 ISGA 为轻度或中度的患者。

关键数值与推荐

  • 主要终点为第 29 天 ISGA 达到清除或几乎清除且较基线改善≥2 级。
  • 次要终点包括第 29 天 ISGA 清除或几乎清除的比例及 ISGA 成功时间。
  • 其他终点包括瘙痒严重度和 AD 体征(红斑、渗出、抓痕、硬结/丘疹和苔藓化),采用 4 级评分(无、轻、中、重)。

临床怎么用

  • 克立硼罗可作为轻中度 AD 的外用治疗选择,尤其适用于改善瘙痒和体征。
  • 临床决策时应考虑两项试验主要终点结果的不一致性。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To assess the efficacy and safety of crisaborole ointment, a phosphodiesterase 4 inhibitor, for the treatment of mild or moderate atopic dermatitis (AD) in two phase III studies (AD-301 and AD-302). DESIGN AND SETTING: Two identically designed multicentre, double-blind randomized controlled trials were conducted in the U.S.A. Participants were randomized 2 : 1 to receive crisaborole or vehicle treatment. In total 47 and 42 investigational centres were identified for AD-301 and AD-302, respectively. STUDY PARTICIPANTS: Inclusion criteria were identified as age ≥ 2 years, clinical diagnosis of AD (as per the Hanifin and Rajka criteria), ≥ 5% body surface area involvement, and baseline Investigator's Static Global Assessment (ISGA) mild or moderate. Exclusion criteria included previous use of biologics or systemic corticosteroids (within the last 28 days) or a topical calcineurin inhibitor/corticosteroid (within the last 14 days), and active skin infection. EXPOSURES: Participants were instructed to apply the study drug twice daily to all lesions identified at baseline, and all new lesions identified after day 1 (with weekly review of application instructions). Bland emollients were permitted to be used on skin not treated with the study drug. PRIMARY OUTCOME: The primary outcome was defined as ISGA clear or almost clear at day 29, with a 2-grade or more improvement from baseline. OUTCOMES: Secondary outcomes included the proportion of patients with an ISGA score of clear or almost clear at day 29, and time to success in ISGA score. Additional outcomes included pruritus severity and signs of AD (erythema, exudation, excoriation, induration/papulation and lichenification), and were measured on a 4-point scale (none, mild, moderate, severe). Adverse events were also recorded. RESULTS: More participants in the crisaborole-treated group achieved ISGA scores of clear or almost clear with ≥ 2-grade improvement than in the vehicle-treated group (AD-301, 32·8% vs. 25·4%, P = 0·38; AD-302, 31·4% vs. 18·0%, P < 0·001). Greater percentages of clear and almost clear scores were observed in the treatment groups (51·7% vs. 40·6%, P = 0·005; 48·5% vs. 29·7%; P < 0·001), as well as earlier success in ISGA score and improvement in pruritus (P ≤ 0·001). No serious treatment-related adverse events were identified. CONCLUSIONS: Based on the study results, the authors suggest that crisaborole is a safe treatment that improves disease severity, pruritus and clinical signs associated with AD.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Ahmed A, Solman L, Williams HC, et al. Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal. Br J Dermatol. 2017. PMID: 29205284. doi:10.1111/bjd.16046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。